Review : Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)
Pastick, Katelyn A. (Department of Medicine. University of Minnesota)
Okafor, Elizabeth C. (Department of Medicine. University of Minnesota)
Wang, Fan (Department of Experimental and Clinical Pharmacology. University of Minnesota)
Lofgren, Sarah M. (Department of Medicine. University of Minnesota)
Skipper, Caleb P. (Department of Medicine. University of Minnesota)
Nicol, Melanie R. (Department of Experimental and Clinical Pharmacology. University of Minnesota)
Pullen, Matthew F. (Department of Medicine. University of Minnesota)
Rajasingham, Radha (Department of Medicine. University of Minnesota)
McDonald, Emily G. (Clinical Practice Assessment Unit. Department of Medicine. McGill University Health Centre)
Lee, Todd C. (Clinical Practice Assessment Unit. Department of Medicine. McGill University Health Centre)
Schwartz, Ilan S. (Division of Infectious Diseases. Department of Medicine. Faculty of Medicine and Dentistry. University of Alberta)
Kelly, Lauren E. (Department of Pediatrics and Child Health. Department of Pharmacology. University of Manitoba)
Lother, Sylvain A. (Department of Medicine. Sections of Critical Care and Infectious Diseases. University of Manitoba)
Mitjà, Oriol (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Letang, Emili (Barcelona Institute for Global Health (ISGlobal))
Abassi, Mahsa (Department of Medicine. University of Minnesota)
Boulware, David R. (Department of Medicine. University of Minnesota)

Date:	2020
Abstract:	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
Grants:	Instituto de Salud Carlos III JR19/00002
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article de revisió ; Article ; Versió publicada
Subject:	Chloroquine ; Clinical trials ; Coronavirus ; COVID-19 ; SARS-CoV-2 ; Hydroxychloroquine
Published in:	Open Forum Infectious Diseases, Vol. 7 Núm. 4 (16 2020) , p. ofaa130, ISSN 2328-8957

DOI: 10.1093/ofid/ofaa130
PMID: 32363212

9 p, 240.3 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Published articles